Navigation Links
BioMS Medical announces second quarter 2009 results
Date:7/17/2009

--------- -------------------- -------------------- Foreign exchange gain on cash and cash equivalents held in foreign currency 4,399 1,550 1,239 1,381 (796) --------- -------------------- -------------------- (Decrease) increase in cash and cash equivalents 64,864 (22,962) 60,370 (10,865) (10,648) Cash and cash equivalents - Beginning of period - 87,826 35,428 75,729 106,446 --------- -------------------- -------------------- Cash and cash equivalents - End of period 64,864 64,864 95,798 64,864 95,798 --------- -------------------- -------------------- --------- -------------------- -------------------- Cash and cash equivalents consists of Bank accounts 1,282 1,282 1,261 1,282 1,261 Interest bearing deposits and securities 63,582 63,582 94,798 63,582 94,537 --------- -------------------- -------------------- 64,864 64,864 95,798 64,864 95,798 --------- -------------------- -------------------- --------- -------------------- --------------------


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
2. BioMS Medical to participate in panel session at Bio International Convention 2009
3. BioMS Medical Announces First quarter 2009 results
4. BioMS Medical to present at Alberta Economic Forum in Geneva
5. BioMS Medical to present at BioFinance 2009
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. BioMS Medical Announces 2008 Year End Results
9. BioMS Medical warrant extension
10. BioMS Medical to present at BIO CEO and Investor Conference
11. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... LANSING, Mich., July 22, 2014  Neogen Corporation (NASDAQ: ... its 2014 fiscal year, which ended May 31, increased ... net income was $28,158,000, compared to the prior year,s ... 30, 2013, earnings per share in the current year ... revenues and net income for the 2014 fiscal year ...
(Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... July 22, 2014  United Therapeutics Corporation (NASDAQ: ... will release its second quarter 2014 financial results ... United Therapeutics will host a half-hour ... a.m. Eastern Time.  The teleconference is accessible by ... rebroadcast of the teleconference will be available for ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Williams ... those who have recognized that the greatest health care ... far too often needlessly deadly while trying to serve ... of quasi-experts seeking to transform an enormous system that ... Dr. Williams, in his continuing series of Open Letters ...
Breaking Biology Technology:Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
... in Key Markets, Differentiated Product Offerings and ... Performance, CARY, N.C., Jan. 10 ... significant milestone with the signing of its ... additional customers during the,second half of 2007. ...
... LONDON, January 10 Amarin Corporation plc,(NASDAQ: AMRN ... and ethical approvals to commence a Phase IIa trial ... The Phase IIa trial will be a randomized, ... AAMI who,will be randomized to receive 1, 2 or ...
... Essilor International,s US subsidiary, has strengthened its,prescription laboratory ... Interstate Optical Co., one of the country,s five ... and,Indianapolis, Indiana serve eye care professionals in 32 ... and 210 employees., Present for more than ...
Cached Biology Technology:SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 2SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 3SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 4Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 2Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 3Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 4
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST), ... dramatically improved technique for analyzing biological cells and ... new NIST technique is an advanced form of ... that delivers signals that are 10,000 times stronger ... times stronger than obtained from comparable "coherent Raman" ...
(Date:7/22/2014)... N.C. In a cost-effectiveness analysis of commercial diet ... drug Qsymia showed the best value for the money. ... but was also the most expensive option tested, according ... Medical School. , The findings, published in the June ... information on the health and weight-loss benefits per dollar ...
(Date:7/22/2014)... Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor of ... Orleans School of Nursing, contributed samples used in ... associated with schizophrenia and also suggesting a possible ... study, Biological insights from 108 schizophrenia-associated genetic loci, ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
... In order for medical students to ultimately provide quality patient ... teach physiology, one of the core disciplines of medicine, according ... Journal of the American College of Radiology ( www.jacr.org ... systems. "It is vital that medical schools provide ...
... Avantra Biosciences (Avantra) today announced the selection ... test site for Avantra,s new biomarker quantitation platform. ... has created an automated multiplex immunoassay system to ... patient characteristics, and drug responses. The new Q400 ...
Cached Biology News:Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Avantra Biosciences teams with TGen Drug Development to assist pharma 2
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
... (patent pending) was developed using a protein engineering ... DNA binding pocket of wild-type DNase I. These ... for DNA. The result is a versatile enzyme ... and an ability to maintain at least 50% ...
Request Info...
Biology Products: